Colorectal Cancer Emergencies

A. Barnett,Anna Cedar,Faisal A Siddiqui,D. Herzig,Emilie Fowlkes,Charles R. Thomas

DOI: https://doi.org/10.1007/s12029-012-9468-0

2013-02-01

Journal of Gastrointestinal Cancer

Abstract:

What problem does this paper attempt to address?

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Chenyi Ren,He Cao,Jing Zheng,Wenjia Sun,Jianya Zhou

DOI: https://doi.org/10.3779/j.issn.1009-3419.2023.102.14

2023-01-01

Abstract:Lung cancer is the most common malignancy in the world and the leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive non-small cell lung cancer (NSCLC) refers to the NSCLC caused by mutation, amplification or overexpression of the HER2 gene, resulting in its dysfunction. HER2 is the most active receptor in the HER family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. In NSCLC, HER2 positivity is usually considered a poor prognostic marker. At present, the diagnosis and treatment of HER2-positive NSCLC are not mature. Immunohistochemistry (IHC), next generation sequencing (NGS) and other technologies are often used to detect the positive status of HER2 mutation, amplification or overexpression. In previous studies, antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC. However, in recent years, related researches have shown that antibody-drug conjugates (ADCs) and new tyrosine kinase inhibitors (TKIs) in targeted therapy show good antitumor activity against HER2 positive NSCLC. This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches. .
Recent progress in targeted therapy for non-small cell lung cancer

Yajun Lin,Yanxia Xiao,Pu Liu,Jie Wei,Xin Zhang,Jun Guo

DOI: https://doi.org/10.3389/fphar.2023.1125547

IF: 5.6

2023-02-22

Frontiers in Pharmacology

Abstract:The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people's health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients has greatly improved. However, in a large number of non-small cell lung cancer cases, the carcinogenic driver is unknown. Identifying genetic alterations is critical for effective individualized therapy in NSCLC. Moreover, targeted drugs are difficult to apply in the clinic. Cancer drug resistance is an unavoidable obstacle limiting the efficacy and application of targeted drugs. This review describes the mechanisms of targeted-drug resistance and newly identified non-small cell lung cancer targets (e.g., KRAS G12C, NGRs, DDRs, CLIP1-LTK, PELP1, STK11/LKB1, NFE2L2/KEAP1, RICTOR, PTEN, RASGRF1, LINE-1, and SphK1). Research into these mechanisms and targets will drive individualized treatment of non-small cell lung cancer to generate better outcomes.

pharmacology & pharmacy
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Min Yuan,Li-Li Huang,Jian-Hua Chen,Jie Wu,Qing Xu

DOI: https://doi.org/10.1038/s41392-019-0099-9

IF: 39.3

2019-12-01

Signal Transduction and Targeted Therapy

Abstract:Abstract Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

biochemistry & molecular biology,cell biology
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Le Yu,Ruoyi Yang,Zeng Long,Qingxiu Tao,Bin Liu

DOI: https://doi.org/10.3389/fonc.2024.1451230

IF: 4.7

2024-09-27

Frontiers in Oncology

Abstract:Lung cancer is a leading cause of cancer-related deaths globally, and traditional chemotherapy has limited efficacy in treating advanced non-small cell lung cancer (NSCLC). In recent years, the prognosis for patients with NSCLC has significantly improved due to the development of new treatment modalities, including targeted therapies. Targeted therapies utilize monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), or small molecule tyrosine kinase inhibitors (TKIs) directed against specific mutated genes such as EGFR and ALK. The development of these drugs has deepened our understanding of NSCLC and improved treatment outcomes for patients. This review aims to summarize the mechanisms and current status of targeted therapy for NSCLC, discuss strategies to overcome acquired resistance, and address current challenges in the field.

oncology
Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

TAN Fen-lai,WANG Yin-xiang,YUAN Xiao-fen,DING Lie-ming,HU Bei,ZHANG Li,ZHOU Jian-ying,SHENG-TU Jian-zhong,SUN Yan

2011-01-01

Abstract:Non-small cell lung cancer(NSCLC) is the leading cause of cancer mortality worldwide.The management of NSCLC has changed dramatically in the last decade.A number of well documented clinical studies demonstrated that the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) showed a better survival benefit comparing to the standard treatments in patients with advanced/metastatic NSCLC.EGFR-TKIs,including gefitinib and erlotinib,have been used in first-line,second-line and more other settings with obvious survival benefits in a subgroup of patients with EGFR mutations.Moreover,icotinib,a novel EGFR-TKIs developed by BetaPharma Inc.,has finished its phase III trial(ICOGEN) with encouraging efficacy and safety profile in China recently.This review will summarize the results of clinical trials of erlotinib,gefitinib or icotinib for patients with advanced NSCLC.
Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Joan Minguet,Katherine H Smith,Peter Bramlage

DOI: https://doi.org/10.1002/ijc.29915

2016-06-01

Abstract:Non-small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor prognosis once the disease has progressed past the point at which surgery is a viable option. Whilst chemotherapy has improved survival over recent decades, there is still great need for improvements in treatments for patients with advanced disease. Over the last decade, a variety of such drugs have received market approval for treating NSCLC, with a variety of others in the pipeline. Here, we review the development of targeted therapies for the treatment of advanced or metastatic NSCLC, including those already in clinical practice and those in early trials. The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. Moreover, the discovery of EGFR mutations and ALK rearrangements has enabled the identification of patients who are more likely to benefit from a specific drug. The recent approval of the immune checkpoint inhibitor nivolumab, along with the designation of alectinib and MPDL3280A as breakthrough therapies by the FDA, demonstrates how rapidly this area of research is expanding. Over the last decade there has been significant progress made in the treatment of advanced NSCLC, and the large and varied selection of drugs currently undergoing trials provide great promise for improving the prognosis of this highly prevalent and deadly form of cancer.
Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Zhen-Xi Niu,Ya-Tao Wang,Nan Lu,Jin-Feng Sun,Peng Nie,Piet Herdewijn

DOI: https://doi.org/10.1016/j.ejmech.2023.115868

IF: 7.088

2023-10-15

European Journal of Medicinal Chemistry

Abstract:Lung cancer continues to pose a significant challenge as a prominent contributor to global cancer-related mortality. Despite the considerable strides made in therapeutic interventions within the past decade, a substantial population of patients diagnosed with non-small cell lung cancer (NSCLC) still face the grim reality of an incurable condition. In the realm of optimal management strategies for individuals afflicted with locally advanced, yet amenable to surgical resection, NSCLC, a therapeutic approach encompassing chemoradiation stands as a fundamental component. Significant strides have been made in the therapeutic landscape of NSCLC during the preceding two decades, facilitating an enhanced comprehension of the underlying disease biology, and mechanisms governing tumor progression, as well as advancements in early detection modalities and multimodal therapeutic interventions. Nevertheless, the overall rates of curative interventions and survival outcomes for NSCLC continue to exhibit a discouragingly low trajectory, particularly in the context of metastatic disease. Hence, the imperative for sustained research endeavors in the realm of novel pharmaceutical agents and combinatorial therapeutic approaches remains paramount, with the overarching objective of broadening the scope of clinical advantages conferred upon a wider demographic of patients, thereby fostering tangible improvements in outcomes pertaining to NSCLC. The primary objective of this review is to provide an all-encompassing examination encompassing the clinical application and synthetic routes of specific drugs, with the explicit aim of disseminating invaluable knowledge that can inform future research and development endeavors focused on NSCLC.

chemistry, medicinal
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Zixi Wang,Yurou Xing,Bingjie Li,Xiaoyu Li,Bin Liu,Yongsheng Wang

DOI: https://doi.org/10.1186/s43556-022-00107-x

2022-12-13

Molecular Biomedicine

Abstract:Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in 2004 represented the beginning of the precision medicine era for this refractory disease. This great progress benefits from the identification of driver gene mutations, and after that, conventional and new technologies such as NGS further illustrated part of the complex molecular pathways of NSCLC. More targetable driver gene mutation identification in NSCLC patients greatly promoted the development of targeted therapy and provided great help for patient outcomes including significantly improved survival time and quality of life. Herein, we review the literature and ongoing clinical trials of NSCLC targeted therapy to address the molecular pathways and targeted intervention progress in NSCLC. In addition, the mutations in EGFR gene, ALK rearrangements, and KRAS mutations in the main sections, and the less common molecular alterations in MET, HER2, BRAF, ROS1, RET, and NTRK are discussed. The main resistance mechanisms of each targeted oncogene are highlighted to demonstrate the current dilemma of targeted therapy in NSCLC. Moreover, we discuss potential therapies to overcome the challenges of drug resistance. In this review, we manage to display the current landscape of targetable therapeutic patterns in NSCLC in this era of precision medicine.
Noise tolerance of 4-dimensional multi-level modulation formats

M. Eiselt,H. Griesser

DOI: https://doi.org/10.1109/OECC.2012.6276710

2012-07-02

Abstract:A new semi-analytical method to estimate the bit-error ratio of two-polarization IQ modulation constellations is proposed, taking into account bit mapping and a possible non-Gaussian noise distribution. Results are compared to analytical formulas and various 4-dimensional constellations are evaluated.
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Yuan Cheng,Tao Zhang,Qing Xu

DOI: https://doi.org/10.1002/mco2.105

2021-12-01

MedComm

Abstract:Lung cancer still contributes to nearly one-quarter cancer-related deaths in the past decades, despite the rapid development of targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC). The development and availability of comprehensive genomic profiling make the classification of NSCLC more precise and personalized. Most treatment decisions of advanced-stage NSCLC have been made based on the genetic features and PD-L1 expression of patients. For the past 2 years, more than 10 therapeutic strategies have been approved as first-line treatment for certain subgroups of NSCLC. However, some major challenges remain, including drug resistance and low rate of overall survival. Therefore, we discuss and review the therapeutic strategies of NSCLC, and focus on the development of targeted therapy and immunotherapy in advanced-stage NSCLC. Based on the latest guidelines, we provide an updated summary on the standard treatment for NSCLC. At last, we discussed several potential therapies for NSCLC. The development of new drugs and combination therapies both provide promising therapeutic effects on NSCLC.
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Umair Majeed,Rami Manochakian,Yujie Zhao,Yanyan Lou

DOI: https://doi.org/10.1186/s13045-021-01121-2

2021-07-08

Abstract:Abstract Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a subset of patients with actionable mutations, targeted therapy continues to provide durable responses. Advances in molecular and immunohistochemical techniques have made it possible to usher lung cancer into the era of personalized medicine, with the patient getting individualized treatment based on these markers. This review summarizes the recent advances in advanced NSCLC targeted therapy, focusing on first-in-human and early phase I/II clinical trials in patients with advanced disease. We have divided our discussion into different topics based on these agents' mechanisms of action. This article is aimed to be the most current review of available and upcoming targeted NSCLC treatment options. We will also summarize the currently available phase I/II clinical trial for NSCLC patients at the end of each section.

oncology,hematology
Advancements in NSCLC

Jianan Xu,Lin Tian,Wenlong Qi,Qingguo Lv,Tan Wang

DOI: https://doi.org/10.1097/coc.0000000000001088

2024-02-20

American Journal of Clinical Oncology

Abstract:With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the development of innovative treatment strategies is increasingly vital. This review underscores the pivotal role of precision medicine in transforming NSCLC management, particularly through the integration of genomic and epigenomic insights to enhance treatment outcomes for patients. We focus on the identification of key gene mutations and examine the evolution and impact of targeted therapies. These therapies have shown encouraging results in improving survival rates and quality of life. Despite numerous gene mutations being identified in association with NSCLC, targeted treatments are available for only a select few. This paper offers an exhaustive analysis of the pathogenesis of NSCLC and reviews the latest advancements in targeted therapeutic approaches. It emphasizes the ongoing necessity for research and development in this domain. In addition, we discuss the current challenges faced in the clinical application of these therapies and the potential directions for future research, including the identification of novel targets and the development of new treatment modalities.

oncology
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Haiyang Guo,Jun Zhang,Chao Qin,Hang Yan,Tao Liu,Haiyang Hu,Shengjie Tang,Shoujun Tang,Haining Zhou

DOI: https://doi.org/10.3390/cells11203200

IF: 6

2022-10-13

Cells

Abstract:Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.

cell biology
A pharmacological exploration of targeted drug therapy in non-small cell lung cancer

Ajay P. Jayan,K. R. Anandu,Krishnadas Madhu,V. N. Saiprabha

DOI: https://doi.org/10.1007/s12032-022-01744-6

2022-07-15

Medical Oncology

Abstract:Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85% from non-small cell lung cancer. Before a few decades back, conventional chemotherapy was the most chosen treatment option for NSCLC but with side effects. Now, the treatment approaches have shifted to a new trend, targeted therapy, and a better treatment strategy with minimal side effects compared to chemotherapy. Advances in technologies and understanding the pathways lead to the discovery of new targets and through which it is possible to improve treatment outcomes and patient compliance. Unlike chemotherapy, targeted therapy focuses on the tumor cells and does not produce toxicity to healthy cells. The last two decades were very crucial in the development of many small molecules with the capability to target-specific proteins or genes in the disease progression pathway. Although the targeted therapy approach was a gemstone with many successful drugs for the treatment of NSCLC, various resistance mechanisms and activation of bypass signaling pathways put many of these drugs in the trash. In this review, we will discuss the major targeted proteins involved in NSCLC as well as the inhibitor drugs developed to target them for now and along with the future directions.

oncology
Research status of targeted agents for the treatment of non-small cell lung cancer

Tan ZHANG,Yi-tong WANG,Yi FANG

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2017.11.029

2017-01-01

Abstract:Objective Non-small cell lung cancer (NSCLC) occupied the most parts of the lung cancer with more than 85％ patients.And the clinical drug therapy had become the key point of the NSCLC in that the most patients of NSCLC were in middle or terminal stage as they are diagnosed.Now,the NSCLC patients can live longer than before with the help of development of targeted agents,besides,the drug therapy methods had enriched by individualized treatment concept.All these methods have brought the great gifts for the non-small cell lung cancer patients.This paper concludes the latest targeted agents for non-small lung cancer patients.
Recent advances in non-small cell lung cancer targeted therapy; an update review

Mahmood Araghi,Reza Mannani,Ali Heidarnejad maleki,Adel Hamidi,Samaneh Rostami,Salar Hozhabri Safa,Fatemeh Faramarzi,Sahar Khorasani,Mina Alimohammadi,Safa Tahmasebi,Reza Akhavan-Sigari

DOI: https://doi.org/10.1186/s12935-023-02990-y

IF: 6.429

2023-08-12

Cancer Cell International

Abstract:Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational research. Among the hopeful breakthroughs in therapeutic approaches, advances in targeted therapy have brought the most successful outcomes in NSCLC treatment. In targeted therapy, antagonists target the specific genes, proteins, or the microenvironment of tumors supporting cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer treatment and the quality of life of patients. Treatment with targeted therapy for NSCLC is changing rapidly due to the pace of scientific research. Accordingly, this updated study aimed to discuss the tumor target antigens comprehensively and targeted therapy-related agents in NSCLC. The current study also summarized the available clinical trial studies for NSCLC patients.

oncology
Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

SONG Yong,YANG Wen

DOI: https://doi.org/10.11855/j.issn.0577-7402.2015.01.03

2015-01-01

Medical Journal of Chinese People's Liberation Army

Abstract:Non-small cell lung cancer is the most common pathological type of lung cancer. Along with the rising incidence in recent years, lung cancer has been the leading cause of death due to malignancies both in our country and worldwide. Due to simplistic therapeutic approach for lung cancer decades ago, those patients suffering from advanced lung cancer had short lifetime, and it was difficult to ensure their life quality. In recent years, many molecular targeted drugs, such as Gefitinib, Erlotinib and Crizotinib etc., have been successively applied in clinical use, and they bring about a substantial prolongation of survival life and improvement in life quality of those patients with advanced lung cancer. In 2014, there was a number of important reports concerning the diagnosis and treatment of non-small cell lung cancer in the annual meetings of either American Society of Clinical Oncology or European Society for Medical Oncology. On the basis of the relevant reports delivered in the conferences, it is our attempt to summarize the recent advances in regard to chemotherapy, molecular targeted therapy, measures to treat TKI therapy resistant cases, and immune therapy, followed by a comment regarding recent advances in the treatment of non-small cell lung cancer in 2014. DOI: 10.11855/j.issn.0577-7402.2015.01.03
Target Therapy of Non-Small Cell Lung Cancer Directed by Biomarkers

DUAN Jian-chun,WANG Jie

DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2010.09.004

2010-01-01

Abstract:Lung cancer is one of the most frequent malignant tumors. Target therapy is a milestone of non-small cell lung cancer (NSCLC) treatment in the 21st century. Biomarker detections have provided a solid foundation for individualized treatment. This review mainly focused on significance of EGFR mutation detection in EGFR tyrosine kinase inhibitors (EGFR-TKIs) as first line, second line and maintenance therapy in NSCLC. Simultaneously, this review introduced predicting significance of EGFR FISH test for the response of TKI treatment, and analyzed potential predictive biomarkers for antiangiogenic agents and status of antiEGFR monoclonal antibody in NSCLC individual therapy.
Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

Shutong Li,Aoxue Wang,Yongya Wu,Shengyuan He,Wen Shuai,Min Zhao,Yumeng Zhu,Xiuying Hu,Yubin Luo,Guan Wang

DOI: https://doi.org/10.1111/imr.13274

2023-09-10

Immunological Reviews

Abstract:Summary Non‐small‐cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a very poor prognosis and a very low chance of survival. Human cancers are closely linked to regulated cell death (RCD), such as apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Currently, small‐molecule compounds targeting various types of RCD have shown potential as anticancer treatments. Moreover, RCD appears to be a specific part of the antitumor immune response; hence, the combination of RCD and immunotherapy might increase the inhibitory effect of therapy on tumor growth. In this review, we summarize small‐molecule compounds used for the treatment of NSCLC by focusing on RCD and pharmacological systems. In addition, we describe the current research status of an immunotherapy combined with an RCD‐based regimen for NSCLC, providing new ideas for targeting RCD pathways in combination with immunotherapy for patients with NSCLC in the future.

immunology
Top advances of the year: Targeted therapy for lung cancer

Maisam Makarem,Pasi A. Jänne

DOI: https://doi.org/10.1002/cncr.35423

IF: 6.9209

2024-06-23

Cancer

Abstract:The past year has offered significant advancements in the field of non–small cell lung cancer (NSCLC), both in the early and advanced disease settings. The identification of guideline‐recommended actionable targets has provided the foundation for developing multiple new therapeutic agents. There has been a focus on developing drugs designed to overcome acquired resistance, a limitation of tyrosine kinase inhibitor–based therapy in lung cancer. In addition, there is an emerging trend toward combination therapies for patients in the first‐line setting with the goal of preventing or delaying resistance. Another promising area of development has been the use of antibody–drug conjugates, where there are the initial reports of central nervous system efficacy and activity in patients with genomic alterations. Over the past year, numerous publications and presentations have highlighted multiple therapeutic advances, offering new treatment options for patients with NSCLC. The focus of this review is to summarize the most impactful findings, emphasizing their significance in the evolving treatment landscape for NSCLC. Several landmark trials in lung cancer with practice‐changing clinical implications have been presented and published in 2023. This article reviews a selection of these trials as they relate to early and advanced‐stage oncogene‐driven lung cancer. The ADAURA and ALINA trials, in which targeted therapy given in the adjuvant setting has demonstrated improved clinical outcomes, are reviewed. In the advanced‐stage setting, recent trials in the context of specific oncogene drivers are reviewed, including EGFR, ALK, ROS1, RET, ERBB2 (HER2), BRAF, MET exon 14 skipping (METex14), and KRAS alterations. Also discussed are the results of several trials that have evaluated the use of combination therapies and resistance‐mechanism agnostic treatment strategies. Plain Language Summary Targeted therapy plays an important role for patients with early and advanced‐stage non–small cell lung cancer carrying specific genetic alterations. New strategies that combine multiple therapies are now being studied in randomized clinical trials, with the goal of enhancing the effectiveness of targeted therapy for patients with advanced lung cancer.

oncology

Colorectal Cancer Emergencies

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Recent progress in targeted therapy for non-small cell lung cancer

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Noise tolerance of 4-dimensional multi-level modulation formats

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Advancements in NSCLC

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

A pharmacological exploration of targeted drug therapy in non-small cell lung cancer

Research status of targeted agents for the treatment of non-small cell lung cancer

Recent advances in non-small cell lung cancer targeted therapy; an update review

Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

Target Therapy of Non-Small Cell Lung Cancer Directed by Biomarkers

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

Top advances of the year: Targeted therapy for lung cancer